GSK plc announced positive headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed… read more.
Janssen Pharmaceutical has filed a new drug application in Japan for its oral fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor erdafitinib for the treatment of certain patients… read more.
BeiGene, Ltd. announced that the European Commission (EC) has granted marketing authorization for Brukinsa (zanubrutinib) in combination with obinutuzumab for the treatment of adult patients with relapsed or… read more.
Redispensing cancer drugs reduces both environmental impact and medical costs, according to research from Radboudumc pharmacy published in JAMA Oncology. The annual savings could amount to tens of millions…. read more.
Roche announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of subcutaneous (SC, or under the skin). Tecentriq (atezolizumab)…. read more.
Patients undergoing radiation therapy for certain types of cancer at Henry Ford West Bloomfield Hospital are among the first in the country with access to a cutting-edge treatment system that… read more.
New materials developed at the University of Surrey could pave the way for a new generation of flexible X-ray detectors, with potential applications ranging from cancer treatment to… read more.
Mirati Therapeutics, Inc. a commercial stage biotechnology company, announced the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) granted conditional marketing authorization approval for Krazati (adagrasib) as… read more.
Women who get a false-positive mammogram reading are more likely to develop breast cancer over the ensuing 20 years, researchers reported on Nov. 2, 2023 in JAMA Oncology. As… read more.
Prepared infusions of nanoparticle albumin-bound (nab) paclitaxel are stable for seven days, when stored in a refrigerator, according to researcher Helen Linxweiler (University Medical Centre of Johannes Gutenberg… read more.
Eli Lilly and Company announced five-year outcomes from a pre-planned analysis of the Phase III monarchE study evaluating two years of adjuvant Verzenio (abemaciclib) in combination with endocrine… read more.
An overwhelming majority of adults (93%) recognize a lump as a symptom of breast cancer, but less than half recognize other common symptoms associated with the disease, according… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
